The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need.

The 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways, to unveiling critical preclinical insights, discussing formulation strategies, defining the optimal clinical development plans or evaluating commercialization approaches.

Join peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion, sharing of latest advances and pioneering insights, and networking opportunities.

Hear from 30+ experts including:

• Sonya Abraham, Head of New Treatment Strategies, Immunology, UCB
• David Rubenstein, CSO, Dermavant Sciences
• Kendall Marcus, Director – Division of Dermatology & Dental Products, FDA
• Michael Kuligowski, Executive Medical Director – Inflammation & Autoimmunity, Incyte Corporation
• John Harris, Vice Chair of Dermatology & Director, Vitiligo Clinic & research Center, University of Massachusetts Medical School
• Suma Krishnan, Founder & COO, Krystal Biotech

Across an end-to-end, comprehensive agenda, learn from case studies on:

• How to enhance preclinical activities
• The latest advances in translational research
• How to advance topical drug development and formulation approaches
• How to accelerate clinical development and what are the latest clinical results
• How to tackle the evolving regulatory and commercial landscape in dermatology

Find out more here: https://ter.li/jj7wxg